Match!

What Can We Expect from Value-Based Funding of Medicines? A Retrospective Study

Published on Apr 1, 2016in PharmacoEconomics3.71
· DOI :10.1007/s40273-015-0354-z
Anthony Harris43
Estimated H-index: 43
,
Jing Jing Li7
Estimated H-index: 7
,
Karen Kah Leng Yong2
Estimated H-index: 2
Abstract
Objective Deciding on public funding for pharmaceuticals on the basis of value for money is now widespread. We suggest that evidence-based assessment of value has restricted the availability of medicines in Australia in a way that reflects the relative bargaining power of government and the pharmaceutical industry. We propose a simple informal game-theoretic model of bargaining between the funding agency and industry and test its predictions using a logistic multiple regression model of past funding decisions made by the Pharmaceutical Benefits Advisory Committee in Australia.
  • References (17)
  • Citations (3)
References17
Newest
#1Mikael Svensson (Örebro University)H-Index: 17
#2Fredrik NilssonH-Index: 2
Last.Karl ArnbergH-Index: 1
view all 3 authors...
34 CitationsSource
#1Simon Eckermann (UOW: University of Wollongong)H-Index: 20
#2Brita A. K. Pekarsky (UniSA: University of South Australia)H-Index: 2
28 CitationsSource
23 CitationsSource
#1Valérie Paris (OECD: Organisation for Economic Co-operation and Development)H-Index: 9
#2Annalisa Belloni (OECD: Organisation for Economic Co-operation and Development)H-Index: 8
56 CitationsSource
8 CitationsSource
#1Marc A. Koopmanschap (Erasmus University Medical Center)H-Index: 53
#2Elly A. Stolk (Erasmus University Medical Center)H-Index: 30
Last.Xander Koolman (TU Delft: Delft University of Technology)H-Index: 21
view all 3 authors...
49 CitationsSource
#1Anthony HarrisH-Index: 43
#2Suzanne Hill (University of Newcastle)H-Index: 31
Last.Emily Walkom (University of Newcastle)H-Index: 9
view all 5 authors...
151 CitationsSource
#1Elizabeth DocteurH-Index: 9
#2Valérie ParisH-Index: 9
Last.Pierre MoïseH-Index: 8
view all 3 authors...
91 Citations
#1Livio Garattini (Mario Negri Institute for Pharmacological Research)H-Index: 23
#2Dante Cornago (Mario Negri Institute for Pharmacological Research)H-Index: 7
Last.Paola De Compadri (Mario Negri Institute for Pharmacological Research)H-Index: 6
view all 3 authors...
52 CitationsSource
#1Paul Tappenden (University of Sheffield)H-Index: 33
#2John Brazier (University of Sheffield)H-Index: 74
Last.Jim Chilcott (University of Sheffield)H-Index: 35
view all 4 authors...
43 CitationsSource
Cited By3
Newest
#1Peter Ghijben (Monash University)H-Index: 4
#2Yuanyuan Gu (Macquarie University)H-Index: 6
Last.Silva Zavarsek (Monash University)H-Index: 9
view all 4 authors...
4 CitationsSource
#1Kathryn M Antioch (Monash University)H-Index: 4
#2Michael Drummond (Ebor: University of York)H-Index: 72
Last.Hindrik VondelingH-Index: 14
view all 4 authors...
7 CitationsSource
#1Afschin Gandjour (Frankfurt School of Finance & Management)H-Index: 11
Source
View next paperCorrection: What Is the Role of Informal Healthcare Providers in Developing Countries? A Systematic Review